Results of antiemetic management in terminal illness.
A wide variety of causes may be responsible for nausea and vomiting in terminal illness. The different emetic stimuli reach the vomiting centre by a variety of pathways and can be blocked by specific antiemetics that act at the neurotransmitter receptor sites in these pathways. A knowledge of the neurotransmitter receptor antagonist potency of the different antiemetics allows the choice of the most appropriate antiemetic for the relief of the nausea and vomiting caused by a particular emetic stimulus. To demonstrate the efficacy of this approach to the management of nausea and vomiting in terminal illness, the outcome of antiemetic choice in 100 consecutive episodes is recorded.
Te Omanga Hospice, Lower Hutt, New Zealand.
I
I
Lichter
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000932:Antiemetics / Q000494:pharmacology / Q000627:therapeutic use*; D002985:Clinical Protocols; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000188:drug therapy* / Q000453:epidemiology / Q000209:etiology; D017981:Receptors, Neurotransmitter / Q000187:drug effects; D012008:Recurrence; D012307:Risk Factors; D013727:Terminal Care / Q000379:methods*; D016896:Treatment Outcome; D014839:Vomiting / Q000188:drug therapy* / Q000453:epidemiology / Q000209:etiology
D000932:Antiemetics; D017981:Receptors, Neurotransmitter